TY  - JOUR
AU  - Vekić, Jelena
AU  - Vujčić, Sanja
AU  - Bufan, Biljana
AU  - Bojanin, Dragana
AU  - Al-Hashmi, Khamis
AU  - Al-Rasadi, Khaild
AU  - Stoian, Anca Pantea
AU  - Zeljković, Aleksandra
AU  - Rizzo, Manfredi
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4415
AB  - Disorders of lipoprotein metabolism and glucose homeostasis are common consequences of insulin resistance and usually co-segregate in patients with metabolic syndrome and type 2 diabetes mellitus (DM). Insulin-resistant subjects are characterized by atherogenic dyslipidemia, a specific lipid pattern which includes hypertriglyceridemia, reduced high-density lipoprotein cholesterol level, and increased proportion of small, dense low-density lipoprotein (LDL). Chronic hyperglycemia favors the processes of non-enzymatic glycation, leading to the increased production of advanced glycation end products (AGEs). Apart from direct harmful effects, AGEs are also potent inducers of oxidative stress and inflammation. In addition, increased AGEs’ production may induce further qualitative modifications of small, dense LDL particles, converting them to glycated LDLs. These particles are even more atherogenic and may confer an increased cardiovascular risk. In this narrative review, we summarize the available evidence of the pathophysiological role and clinical importance of circulating AGEs and glycated LDLs in patients with dyslipidemia, particularly those with DM and related complications. In addition, we discuss recent advances and the issues that should be improved regarding laboratory assessment of AGEs and glycated LDLs, as well as the possibilities for their therapeutic modulation.
PB  - MDPI
T2  - Metabolites
T1  - The Role of Advanced Glycation End Products on Dyslipidemia
VL  - 13
IS  - 1
DO  - 10.3390/metabo13010077
ER  - 

@article{
author = "Vekić, Jelena and Vujčić, Sanja and Bufan, Biljana and Bojanin, Dragana and Al-Hashmi, Khamis and Al-Rasadi, Khaild and Stoian, Anca Pantea and Zeljković, Aleksandra and Rizzo, Manfredi",
year = "2023",
abstract = "Disorders of lipoprotein metabolism and glucose homeostasis are common consequences of insulin resistance and usually co-segregate in patients with metabolic syndrome and type 2 diabetes mellitus (DM). Insulin-resistant subjects are characterized by atherogenic dyslipidemia, a specific lipid pattern which includes hypertriglyceridemia, reduced high-density lipoprotein cholesterol level, and increased proportion of small, dense low-density lipoprotein (LDL). Chronic hyperglycemia favors the processes of non-enzymatic glycation, leading to the increased production of advanced glycation end products (AGEs). Apart from direct harmful effects, AGEs are also potent inducers of oxidative stress and inflammation. In addition, increased AGEs’ production may induce further qualitative modifications of small, dense LDL particles, converting them to glycated LDLs. These particles are even more atherogenic and may confer an increased cardiovascular risk. In this narrative review, we summarize the available evidence of the pathophysiological role and clinical importance of circulating AGEs and glycated LDLs in patients with dyslipidemia, particularly those with DM and related complications. In addition, we discuss recent advances and the issues that should be improved regarding laboratory assessment of AGEs and glycated LDLs, as well as the possibilities for their therapeutic modulation.",
publisher = "MDPI",
journal = "Metabolites",
title = "The Role of Advanced Glycation End Products on Dyslipidemia",
volume = "13",
number = "1",
doi = "10.3390/metabo13010077"
}

Vekić, J., Vujčić, S., Bufan, B., Bojanin, D., Al-Hashmi, K., Al-Rasadi, K., Stoian, A. P., Zeljković, A.,& Rizzo, M.. (2023). The Role of Advanced Glycation End Products on Dyslipidemia. in Metabolites
MDPI., 13(1).
https://doi.org/10.3390/metabo13010077

Vekić J, Vujčić S, Bufan B, Bojanin D, Al-Hashmi K, Al-Rasadi K, Stoian AP, Zeljković A, Rizzo M. The Role of Advanced Glycation End Products on Dyslipidemia. in Metabolites. 2023;13(1).
doi:10.3390/metabo13010077 .

Vekić, Jelena, Vujčić, Sanja, Bufan, Biljana, Bojanin, Dragana, Al-Hashmi, Khamis, Al-Rasadi, Khaild, Stoian, Anca Pantea, Zeljković, Aleksandra, Rizzo, Manfredi, "The Role of Advanced Glycation End Products on Dyslipidemia" in Metabolites, 13, no. 1 (2023),
https://doi.org/10.3390/metabo13010077 . .

TY  - JOUR
AU  - Vekić, Jelena
AU  - Zeljković, Aleksandra
AU  - Cicero, Arrigo F. G.
AU  - Janez, Andrej
AU  - Stoian, Anca Pantea
AU  - Sonmez, Alper
AU  - Rizzo, Manfredi
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4063
AB  - Atherosclerosis is responsible for large cardiovascular mortality in many countries globally. It has been shown over the last decades that the reduction of atherosclerotic progression is a critical factor for preventing future cardiovascular events. Low-density lipoproteins (LDL) have been successfully targeted, and their reduction is one of the key preventing measures in patients with atherosclerotic disease. LDL particles are pivotal for the formation and progression of atherosclerotic plaques; yet, they are quite heterogeneous, and smaller, denser LDL species are the most atherogenic. These particles have greater arterial entry and retention, higher susceptibility to oxidation, as well as reduced affinity for the LDL receptor. Increased proportion of small, dense LDL particles is an integral part of the atherogenic lipoprotein phenotype, the most common form of dyslipidemia associated with insulin resistance. Recent data suggest that both genetic and epigenetic factors might induce expression of this specific lipid pattern. In addition, a typical finding of increased small, dense LDL particles was confirmed in different categories of patients with elevated cardiovascular risk. Small, dense LDL is an independent risk factor for cardiovascular diseases, which emphasizes the clinical importance of both the quality and the quantity of LDL. An effective management of atherosclerotic disease should take into account the presence of small, dense LDL in order to prevent cardiovascular complications.
PB  - MDPI
T2  - Medicina
T1  - Atherosclerosis Development and Progression: The Role of
Atherogenic Small, Dense LDL
VL  - 58
IS  - 2
SP  - 299
DO  - 10.3390/medicina58020299
ER  - 

@article{
author = "Vekić, Jelena and Zeljković, Aleksandra and Cicero, Arrigo F. G. and Janez, Andrej and Stoian, Anca Pantea and Sonmez, Alper and Rizzo, Manfredi",
year = "2022",
abstract = "Atherosclerosis is responsible for large cardiovascular mortality in many countries globally. It has been shown over the last decades that the reduction of atherosclerotic progression is a critical factor for preventing future cardiovascular events. Low-density lipoproteins (LDL) have been successfully targeted, and their reduction is one of the key preventing measures in patients with atherosclerotic disease. LDL particles are pivotal for the formation and progression of atherosclerotic plaques; yet, they are quite heterogeneous, and smaller, denser LDL species are the most atherogenic. These particles have greater arterial entry and retention, higher susceptibility to oxidation, as well as reduced affinity for the LDL receptor. Increased proportion of small, dense LDL particles is an integral part of the atherogenic lipoprotein phenotype, the most common form of dyslipidemia associated with insulin resistance. Recent data suggest that both genetic and epigenetic factors might induce expression of this specific lipid pattern. In addition, a typical finding of increased small, dense LDL particles was confirmed in different categories of patients with elevated cardiovascular risk. Small, dense LDL is an independent risk factor for cardiovascular diseases, which emphasizes the clinical importance of both the quality and the quantity of LDL. An effective management of atherosclerotic disease should take into account the presence of small, dense LDL in order to prevent cardiovascular complications.",
publisher = "MDPI",
journal = "Medicina",
title = "Atherosclerosis Development and Progression: The Role of
Atherogenic Small, Dense LDL",
volume = "58",
number = "2",
pages = "299",
doi = "10.3390/medicina58020299"
}

Vekić, J., Zeljković, A., Cicero, A. F. G., Janez, A., Stoian, A. P., Sonmez, A.,& Rizzo, M.. (2022). Atherosclerosis Development and Progression: The Role of
Atherogenic Small, Dense LDL. in Medicina
MDPI., 58(2), 299.
https://doi.org/10.3390/medicina58020299

Vekić J, Zeljković A, Cicero AFG, Janez A, Stoian AP, Sonmez A, Rizzo M. Atherosclerosis Development and Progression: The Role of
Atherogenic Small, Dense LDL. in Medicina. 2022;58(2):299.
doi:10.3390/medicina58020299 .

Vekić, Jelena, Zeljković, Aleksandra, Cicero, Arrigo F. G., Janez, Andrej, Stoian, Anca Pantea, Sonmez, Alper, Rizzo, Manfredi, "Atherosclerosis Development and Progression: The Role of
Atherogenic Small, Dense LDL" in Medicina, 58, no. 2 (2022):299,
https://doi.org/10.3390/medicina58020299 . .